์นผ์ํธ๋ฆฌ์ฌ
์นผ์ํธ๋ฆฌ์ฌ์ ๋นํ๋ฏผ D์ ํ์ฑ ํธ๋ฅด๋ชฌ ํํ์ ๋๋ค. ์์ํ์์๋ ์ฃผ๋ก **์ ์นผ์ํ์ฆ**(์ข ์ข ๋ถ๊ฐ์์ ๊ธฐ๋ฅ ์ ํ์ฆ์ ์๋ฐํจ)์ ๊ด๋ฆฌํ๊ณ ๋ง์ฑ ์ ์ฅ ์งํ(CKD)์์ **์๋ฐ์ฑ ๋ถ๊ฐ์์ ๊ธฐ๋ฅ ํญ์ง์ฆ**์ ์ต์ ํ๋ ๋ฐ ์ฌ์ฉ๋ฉ๋๋ค. ๋ํ ํน์ ๊ฒฌ์ข ์ ์๋ฐ์ฑ ํน๋ฐ์ฑ ์ง๋ฃจ์ฆ ์น๋ฃ์๋ ๋์์ด ๋ ์ ์์ต๋๋ค. > **์์ ์์ :** ๊ฑด๊ฐํ ๋๋ฌผ์ ์ ์ฅ์ 1-์ํ-์์ฐํํจ์๋ฅผ ์์ฑํ์ฌ ๋นํ์ฑ ๋นํ๋ฏผ D๋ฅผ ํ์ฑ ํํ(์นผ์ํธ๋ฆฌ์ฌ)๋ก ๋ณํํฉ๋๋ค. ๋ง์ฑ ์ ๋ถ์ ์์๋ ๊ธฐ๋ฅ์ ์ ์ฅ ์ง๋์ ์์ค๋ก ์ธํด ์ด ํจ์๊ฐ ๊ฒฐํ๋ฉ๋๋ค. ์นผ์ํธ๋ฆฌ์ฌ์ ๋ณด์ถฉํ๋ฉด ์ด๋ฌํ ๋์ฌ ๊ฒฐํจ์ ์ฐํํ์ฌ ๋ถ๊ฐ์์ ํธ๋ฅด๋ชฌ(PTH) ํฉ์ฑ์ ์ง์ ์ ์ผ๋ก ์ต์ ํ๊ณ ์ ์ฅ์ฑ ์๋ฐ์ฑ ๋ถ๊ฐ์์ ๊ธฐ๋ฅ ํญ์ง์ฆ(์ ์ฑ ๊ณจ์ด์์์ฆ)์ ์๋ฐฉํ๊ฑฐ๋ ์น๋ฃํ ์ ์์ต๋๋ค.
์์ฉ ๊ธฐ์ : Calcitriol binds to the intracellular **Vitamin D Receptor (VDR)** in target tissues (intestine, bone, kidney, and parathyroid gland) to regulate calcium and phosphorus homeostasis. * **Intestine:** Upregulates the synthesis of calcium-binding proteins (e.g., calbindin) โ significantly enhances the GI absorption of calcium and phosphorus. * **Kidney:** Promotes renal tubular reabsorption of calcium. * **Parathyroid Gland:** Directly binds to VDRs on the parathyroid gland โ inhibits the transcription of the **PTH** gene, reducing PTH synthesis and secretion. * **Bone:** Works synergistically with PTH to stimulate osteoclast activity, mobilizing calcium and phosphorus into the extracellular fluid. Unlike other forms of vitamin D (like cholecalciferol or ergocalciferol), calcitriol does **not** require hepatic or renal activation, resulting in a rapid onset of action (approximately 1 day) and a short half-life.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- To suppress secondary hyperparathyroidism in CRF ยท 1.5-3.5 nanograms/kg PO daily given separately from meals (or 2.5-3.5 nanograms/kg PO once daily) ยท PO ยท q24h ยท Long-term ยท Remove oil from capsule, dilute in corn oil, then give the appropriate volume.
- Long-term maintenance in animals with hypoparathyroidism ยท 0.03-0.06 micrograms/kg/day ยท PO ยท q24h ยท Long-term ยท Combine with oral calcium to reduce vitamin D dose requirements.
- To suppress secondary hyperparathyroidism in CRF ยท 2.5-3.5 nanograms/kg/day PO (Dogs with refractory hyperparathyroidism may require up to 6 nanograms/kg/day). Alternatively, pulsed-dosing: 20 nanograms/kg twice weekly PO at bedtime on an empty stomach. ยท PO ยท q24h or twice weekly ยท Long-term ยท Confirm CRF (creatinine >2 mg/dL) and reduce hyperphosphatemia to <6 mg/dL before starting.
- Subacute and chronic maintenance treatment of hypocalcemia ยท Initially, 20-30 nanograms/kg/day PO divided twice a day for 3-4 days, then 5-15 nanograms/kg/day divided twice a day ยท PO ยท q12h ยท Initial 3-4 days, then maintenance
- Long-term maintenance in animals with hypoparathyroidism ยท 0.03-0.06 micrograms/kg/day ยท PO ยท q24h ยท Long-term ยท Combine with oral calcium to reduce vitamin D dose requirements.
- Primary idiopathic seborrhea (especially in spaniel breeds) ยท 10 nanograms/kg PO once daily ยท PO ยท q24h ยท Give as far away from the main meal as possible.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Hypercalcemia
- Hyperphosphatemia (Calcium x Phosphorus product > 70)
- Vitamin D toxicity
- Malabsorption syndromes
- Abnormal sensitivity to vitamin D effects
์ด์๋ฐ์
- Hypercalcemia
- Hypercalciuria
- Hyperphosphatemia
- Polydipsia
- Polyuria
- Anorexia
- Tissue mineralization (if given with hyperphosphatemia)
์ฝ๋ฌผ ์ํธ์์ฉ
- Calcium-containing phosphorus binding agents (e.g., calcium carbonate) ยท Use with calcitriol may induce hypercalcemia.
- Corticosteroids ยท Can nullify the effects of vitamin D analogs.
- Digoxin ยท Patients are highly sensitive to the arrhythmogenic effects of hypercalcemia; intensified monitoring is required.
- Verapamil ยท Patients are sensitive to the effects of hypercalcemia; intensified monitoring is required.
- Phenytoin, Barbiturates, Primidone ยท May induce hepatic enzyme systems and increase the metabolism of Vitamin D analogs, thus decreasing their activity.
- Thiazide diuretics ยท May cause hypercalcemia when given in conjunction with Vitamin D analogs.
๋ชจ๋ํฐ๋ง
- Serum calcium (baseline, 1 week, then every 2-4 weeks/6 months depending on protocol)
- Serum phosphorus
- Serum creatinine
- Serum PTH levels (especially in cats or refractory cases)
- Clinical efficacy (improved appetite, activity level, slowed progression of disease)
๊ณผ์ฉ๋
Overdosage can cause **hypercalcemia**, **hypercalciuria**, and **hyperphosphatemia**. * **Acute Ingestion:** Manage using established protocols for GI decontamination. Orally administered mineral oil may reduce absorption and enhance fecal elimination. * **Chronic Overdosage:** Hypercalcemia secondary to chronic dosing should be treated by first temporarily discontinuing (not just dose reduction) calcitriol and exogenous calcium therapy. * **Severe Hypercalcemia:** May require treatment with furosemide, calcium-free IV fluids (e.g., normal saline), urine acidification, and corticosteroids.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.